A Long-acting in situ organo-gel for combination therapy in Alzheimer's Disease

Sanjay Garg – Professor, Adelaide University; haripriya koppisetti – PhD student, Adelaide University; Deepa Nakmode – PhD student, Adelaide University; Weranga Rajapaksha – PhD student, Adelaide University; Yunmei Song – Research Fellow, Adelaide University

Introduction:

Dementia due to Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, projected to affect ~433,300 Australians and 55 million people globally by 2025, with a global management cost of USD 14 trillion by 2050 [1]. AD pathology involves glutamate-induced excitotoxicity and cholinergic deficit, leading to cognitive decline. Currently, FDA-approved therapies include acetylcholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies [2]. Long-acting injectable (LAI) systems, such as in situ forming implants (ISFIs), offer a promising approach to achieve sustained drug delivery and improve treatment compliance in elderly patients.